Ask AI
ProCE Banner Activity

CE

Advancing Anesthesia Safety: The Impact of Ready-To-Administer Injectable Solutions in the OR​ (Enduring Archive)

Video

Advancing Anesthesia Safety: The Impact of Ready-To-Administer Injectable Solutions in the OR​ (Enduring Archive)

Pharmacists: maximum of 1.00 contact hours

Pharmacy Technicians: maximum of 1.00 contact hours

Released: April 22, 2026

Expiration: April 23, 2028

Share

Acknowledgement

This activity is supported by an independent educational grant from Fresenius Kabi USA, LLC

Provider Statement

This activity is jointly provided by Partners for Advancing Clinical Education (Partners) and the Institute for Safe Medication Practices (ISMP)

Learning Objectives

  • Describe the risks associated with the preparation and administration of IV medications that are manipulated in perioperative and procedural care settings

     

  • Compare the safety profiles of manufacturer-prepared ready-to-administer (RTA) products, traditional vial-and-syringe preparations, and products prepared by 503B outsourcing facilities

     

  • Analyze studies evaluating the cost and safety of manufacturer-prepared RTA products versus traditional vial-and-syringe products with attention to evidence evaluating the impact of RTA use on patient outcomes in anesthesia practice

     

Disclosure

Partners requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty Disclosure

Christina Michalek, faculty for this activity, has no relevant financial relationships.

John Hertig, faculty for this activity, has received consultant/advisor/speaker fees from Fresenius Kabi, USA and Omnicell, INC.

Elizabeth Rebello, faculty for this activity, has no relevant financial relationships.

Jana O’Hara, planner for this activity, has no relevant financial relationships.

Rita Jew, planner for this activity, has stocks/stock options in Arrowhead Pharmaceuticals, Cencora, Gilead, GSK, Nvavax, TeleDoc, VaxArt, Vikings Therapeutics.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and ISMP. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Pharmacist Continuing Education
Partners designates this continuing education activity for 1 contact hour(s) (0.10 CEUS) of the Accreditation Council for Pharmacy Education. 
Universal Activity Number - JA4008073-9999-26-142-H05-P/T
Type of Activity: Knowledge

Additional Information

Instructions for Credit

  1. There are no fees for participating in and receiving CE credit for this activity.
  2. During the period April 23, 2026 through April 23, 2028, participants must read the educational objectives and faculty disclosures and study the educational activity.
  3. If you wish to receive acknowledgment for completing this activity, please complete the evaluation.
  4. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
  5. Pharmacists/Technicians: Upon successfully completing the activity evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has posted.

Estimated time to complete activity: 1.0 hour